Previous 10 | Next 10 |
2024-05-03 16:00:00 ET Summary As the wider market turns pessimistic, Eli Lilly continues to trade sideways at these inflated levels with the stock still boasting overly premium valuations, triggering a minimal margin of safety. While LLY's capacity expansions and M&A activiti...
2024-05-03 10:28:54 ET More on Amgen Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet Amgen: I Prefer To Chase Value And Dividends Biggest stock movers today: WOW, AAPL, SQ, and more Amge...
2024-05-03 06:12:44 ET Summary Eli Lilly and Company's stock has seen a significant rally due to excitement about its weight loss drug, Zepbound, among other products. It's a healthy, growing business with higher revenues each year, but adjusting for cash outflows from M&A and...
2024-05-02 19:23:00 ET By almost any measure, Eli Lilly (NYSE: LLY) stock has been a standout so far in 2024. Using a basic yardstick, the pharmaceutical sector giant's share price has climbed by over 33%, against the S&P 500 index's 5%. A mix of well-established commerciali...
2024-05-02 17:40:21 ET More on Amgen Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Amgen Non-GAAP EPS of $3.96 beats by $0.05, revenue of $7.45B in-line ...
2024-05-02 15:10:06 ET More on Eli Lilly, Palatin Tech, etc. Eli Lilly Shoots Higher: It's Time To Be Cautious Eli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And Raise Eli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 Franchise GLP-1 drug pri...
2024-05-02 14:31:50 ET More on Novartis, Novartis AG, etc. Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis AG 2024 Q1 - Results - Earnings Call Presentation Novartis to b...
2024-05-02 09:58:32 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly Shoots Higher: It's Time To Be Cautious Eli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And Raise Eli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 Franchise Novo Nordisk s...
2024-05-02 09:17:44 ET More on Novo Nordisk Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy Novo Nordisk Remains The Better Buy After A Moderate Pullback Novo Nordisk: The Moat Won't Last Forever Novo Nordisk lifts guidance as Ozempic,...
2024-05-02 05:45:00 ET Shares of Eli Lilly and Company (NYSE: LLY) have soared nearly 35% so far in 2024 and are only a few points away from doubling over the last 12 months. The company reigns as the biggest drugmaker in the world based on market cap. It's also the largest company ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 19:06:06 ET It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and Zepbound/Mounjaro for Lilly). In the pharmaceutical industry,...
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement PR Newswire INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024 ....
2024-07-24 06:39:00 ET If you're a dividend investor, you shouldn't bother with stocks that don't raise their payouts. Inflation has drastically chipped away at consumers' purchasing power in recent years, highlighting just how important it is for dividend income to rise over the long run...